Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, USA.
Department of Oncology, The Johns Hopkins Hospital, Baltimore, Maryland, USA.
Diagn Cytopathol. 2020 Jun;48(6):538-546. doi: 10.1002/dc.24417. Epub 2020 Mar 24.
Current clinical practices are shifting towards utilizing less invasive biopsy techniques, including fine needle aspiration (FNA) and needle core biopsies. If a patient has a suspected hematologic malignancy, a portion of the FNA sample is typically submitted for flow cytometry (FC) analysis, providing valuable immunophenotypic data.
FNA specimens were identified via a pathology database search. All cases were morphologic evaluated and a subset of cases were analyzed by FC.
245 hematologic FNA specimens were identified; 84% of these cases had an adequate number of cells for FC analysis, and an unequivocal morphologic diagnosis (benign or malignant) was rendered in 85%. The percentage of cases with an unequivocal diagnosis was statistically significantly higher in those with associated FC than with those without FC (90% vs 58%). Neither FNA technique nor anatomic site affected the likelihood of obtaining an adequate sample for FC analysis and/or rendering a definitive morphologic or unequivocal FC diagnosis. Likewise, tumor subtype did not affect the likelihood of acquiring enough cells for FC analysis, but occasionally resulted in equivocal FC diagnoses or discordant FNA and FC diagnoses. Aggressive B-cell lymphomas and Hodgkin lymphomas were significantly less likely to be detected by FC as compared to low-grade B-cell lymphomas. Discrepancies between FNA and FC diagnoses occurred in 13% of cases. The majority of discrepancies (78%) included FC false negatives, while only 22% of cases had atypical or positive FC with negative FNA.
FNA with associated FC is a powerful diagnostic technique; however, lymphoma subtype may affect diagnostic sensitivity by FC, and therefore, discordant FNA and FC results should be interpreted with caution.
目前的临床实践正在转向使用创伤较小的活检技术,包括细针抽吸(FNA)和针芯活检。如果患者疑似患有血液系统恶性肿瘤,通常会提交一部分 FNA 样本进行流式细胞术(FC)分析,提供有价值的免疫表型数据。
通过病理数据库搜索确定 FNA 标本。所有病例均进行形态学评估,部分病例进行 FC 分析。
共确定 245 例血液学 FNA 标本;其中 84%的病例有足够数量的细胞进行 FC 分析,85%的病例做出明确的形态学诊断(良性或恶性)。与未进行 FC 分析的病例相比,进行 FC 分析的病例中具有明确诊断的比例具有统计学显著差异(90%比 58%)。无论是 FNA 技术还是解剖部位,都不会影响获得足够 FC 分析样本和/或做出明确形态学或明确 FC 诊断的可能性。同样,肿瘤亚型不会影响获得足够 FC 分析细胞的可能性,但偶尔会导致 FC 诊断不确定或 FNA 和 FC 诊断不一致。与低级别 B 细胞淋巴瘤相比,侵袭性 B 细胞淋巴瘤和霍奇金淋巴瘤通过 FC 检测的可能性显著降低。FNA 和 FC 诊断之间存在 13%的差异。大多数差异(78%)包括 FC 假阴性,而只有 22%的病例 FC 呈典型或阳性而 FNA 呈阴性。
FNA 联合 FC 是一种强大的诊断技术;然而,淋巴瘤亚型可能会影响 FC 的诊断敏感性,因此,应谨慎解释不一致的 FNA 和 FC 结果。